文献速递中医内科中药与中成药合理使用中医康复

大黄䗪虫丸治疗下肢外周动脉疾病的多靶点机制与治疗潜力:结构化叙述性综述

Multi-target mechanisms and therapeutic potential of Dahuang Zhechong pill in lower extremity peripheral artery disease: a structured narrative review.
PubMed 文献 · Front Pharmacol · 2026-05-26

本文为结构化叙述性综述,基于预设文献检索策略,汇总大黄䗪虫丸治疗下肢外周动脉疾病的传统理论依据与现代证据。临床研究(多为小样本试验)提示,大黄䗪虫丸作为针灸、活血方或常规治疗的辅助手段,可能与踝肱指数、血脂谱、血液黏度和微循环灌注改善相关,短期安全性信号总体良好。

要点

  • 大黄䗪虫丸辅助治疗下肢PAD可能改善ABI、血脂、血液黏度及微循环灌注。
  • 现有临床证据多来自小样本试验,证据强度有限,需审慎解读。
  • 网络药理学与分子对接结果仅作为假设生成证据,应与实验和临床研究区分。

核心结论

  • 大黄䗪虫丸可能通过多靶点机制对下肢外周动脉疾病相关病理环节产生作用,但当前证据以临床前研究和小样本临床试验为主,尚需高质量研究支持标准化临床应用。

研究设计与样本

  • 本研究为结构化叙述性综述,基于预设的文献检索与研究选择策略,纳入临床前研究、有限临床报告及计算机模拟研究,并将后者视为假设生成证据。

主要发现

  • 临床前研究和有限临床报告提示,大黄䗪虫丸可能与内皮相关指标、脂质代谢、炎症、氧化应激及血液流变学参数等多领域效应相关。
  • 临床研究(多为小样本试验)表明,大黄䗪虫丸作为针灸、活血方或常规治疗的辅助手段,可能与踝肱指数、血脂谱、血液黏度和微循环灌注改善相关,短期安全性信号总体良好。

临床怎么用

  • 在中医辨证属瘀血阻络兼气虚、血热或痰湿等证候的下肢PAD患者中,可考虑将大黄䗪虫丸作为针灸、活血方或常规治疗的辅助用药,但需基于小样本证据审慎评估获益与风险。

局限性

  • 现有临床证据多为小样本试验,证据等级有限;计算机模拟结果仅为假设生成性质,需与体外/体内及临床研究明确区分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lower extremity peripheral artery disease (PAD) is a chronic ischemic disorder primarily driven by atherosclerosis (AS) and characterized by endothelial injury, lipid deposition, inflammation, oxidative stress, and hemorheological abnormalities. From the perspective of traditional Chinese medicine (TCM), its pathogenesis is commonly interpreted within the concept of "Tuoju", in which blood stasis obstructs the collaterals/meridians and may coexist with qi deficiency, blood heat, or phlegm-dampness. Dahuang Zhechong Pill (DHZCP), first recorded in the Jingui Yaolue, is traditionally prescribed to remove blood stasis, clear heat, and resolve masses, while also supporting vital qi and nourishing yin, which conceptually aligns with TCM pattern differentiation in PAD. Preclinical studies and limited clinical reports suggest that DHZCP may be associated with multi-domain effects relevant to PAD pathophysiology, including endothelial-related readouts, lipid metabolism, inflammation, oxidative stress, and hemorheological parameters. Clinical studies (mostly small-sample trials) indicate that DHZCP may be associated with improvements in ankle-brachial index (ABI), lipid profiles, blood viscosity, and microcirculatory perfusion, particularly when used as an adjunct to acupuncture, blood-activating prescriptions, or conventional therapies, with generally favorable short-term safety signals. This review summarizes the traditional rationale and modern evidence on DHZCP for PAD, critically appraises the current evidence base and its limitations, and proposes priorities for future research to support standardized clinical use and potential international application. This article is a structured narrative review based on a predefined literature search and study selection strategy. In silico findings (e.g., network approaches and molecular docking) are treated as hypothesis-generating evidence and are clearly distinguished from in vitro/in vivo and clinical studies.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Teng Y, Zhang Y, Lv B, et al. Multi-target mechanisms and therapeutic potential of Dahuang Zhechong pill in lower extremity peripheral artery disease: a structured narrative review. Front Pharmacol. 2026. PMID: 42272829. doi:10.3389/fphar.2026.1766592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。